文献速递骨质疏松与代谢性骨病

抗骨质疏松治疗提升低骨量患者骨材料强度指数

Treatments of osteoporosis increase bone material strength index in patients with low bone mass.
PubMed 文献 · Osteoporos Int · 2020-04-08

该研究对54例低骨量初治患者进行2年随访,采用体内冲击微压痕(IMI)评估骨材料强度指数(BMSi)。抗骨吸收治疗组BMSi显著升高(82.4±4.3 vs 79.3±4.1,p<0.001),而维生素D±钙对照组无变化(p=0.35);BMSi变化与基线值负相关(r=-0.43,p=0.02),与骨密度变化无关。

要点

  • 抗骨吸收治疗可独立于骨密度提升BMSi。
  • BMSi升高幅度与治疗前基线值负相关。
  • 对照组BMSi大幅下降者出现新发骨折。

核心结论

  • 在骨折风险增高的低骨量患者中,抗骨吸收治疗可诱导不依赖骨密度的BMSi升高,升高幅度取决于治疗前基线值。

研究设计与样本

  • 纳入54例初治低骨量患者(34例女性,中位年龄58岁),治疗组30例接受双膦酸盐或地舒单抗,对照组24例仅用维生素D±钙,随访23.1±6.6个月,用OsteoProbe®行IMI测量BMSi。

主要发现

  • 治疗组BMSi从79.3±4.1升至82.4±4.3(p<0.001),对照组从82.2±4.1变为81.5±5.2(p=0.35)。
  • 抗骨吸收治疗组BMSi变化与基线值负相关(r=-0.43,p=0.02),与骨密度变化无关。
  • 对照组2例BMSi大幅下降者发生新发骨折。

临床怎么用

  • 对低骨量且骨折风险增高的患者,可考虑抗骨吸收治疗以改善骨材料强度。
  • IMI测得的BMSi可作为监测抗骨质疏松治疗效果的补充指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Effects on bone material properties of two-year antiosteoporotic treatment were assessed using in vivo impact microindentation (IMI) in patients with low bone mineral density (BMD) values. Antiresorptive treatment, in contrast to vitamin D ± calcium treatment alone, induced BMD-independent increases in bone material strength index, measured by IMI, the magnitude of which depended on pretreatment values. INTRODUCTION: Bone material strength index (BMSi), measured by IMI in vivo, is reduced in patients with fragility fractures, but there is no information about changes in values during long-term therapy. In the present study, we assessed changes in BMSi in patients receiving antiosteoporotic treatments for periods longer than 12 months. METHODS: We included treatment-naive patients with low bone mass who had a BMSi measurement with OsteoProbe® at presentation and consented to a repeat measurement after treatment. RESULTS: We studied 54 patients (34 women), median age 58 years, of whom 30 were treated with bisphosphonates or denosumab (treatment group) and 24 with vitamin D ± calcium alone (control group). There were no differences in clinical characteristics between the two groups with the exception of a higher number of previous fragility fractures in the treatment group. Baseline hip BMD and BMSi values were lower in the treatment group. After 23.1 ± 6.6 months, BMSi increased significantly in the treatment group (82.4 ± 4.3 vs 79.3 ± 4.1; p < 0.001), but did not change in the control group (81.5 ± 5.2 vs 82.2 ± 4.1; p = 0.35). Changes in BMSi with antiresorptives were inversely related with baseline values (r = - 0.43; p = 0.02) but not with changes in BMD. Two patients in the control group with large decreases in BMSi values sustained incident fractures. CONCLUSION: In patients at increased fracture risk, antiresorptive treatments induced BMD-independent increases in BMSi values, the magnitude of which depended on pretreatment values.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Schoeb M, Malgo F, Peeters JJM, et al. Treatments of osteoporosis increase bone material strength index in patients with low bone mass. Osteoporos Int. 2020. PMID: 32270252. doi:10.1007/s00198-020-05375-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。